See the DrugPatentWatch profile for cosentyx

Reducing the dosage of Cosentyx (secukinumab) may impact remission maintenance in patients with certain inflammatory diseases, such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. However, the specific effects of reduced Cosentyx dosage on remission maintenance are not extensively studied and documented.

Cosentyx is a human monoclonal antibody that selectively neutralizes interleukin-17A (IL-17A), a cytokine involved in the pathogenesis of inflammatory diseases. The recommended dosage for Cosentyx varies depending on the specific condition being treated, but it is generally administered once every 4 weeks [1].

A study published in the Journal of the American Academy of Dermatology investigated the efficacy of dose reduction in psoriasis patients who achieved a stable response to Cosentyx. The study found that dose reduction from 300 mg to 150 mg every 4 weeks did not compromise the efficacy of Cosentyx [2]. However, the study did not specifically focus on remission maintenance.

Another study published in the Annals of the Rheumatic Diseases investigated the efficacy and safety of dose reduction in psoriatic arthritis patients who achieved a stable response to Cosentyx. The study found that dose reduction from 300 mg to 150 mg every 4 weeks did not compromise the efficacy of Cosentyx [3]. However, the study did not specifically focus on remission maintenance.

In conclusion, while some studies suggest that reducing the dosage of Cosentyx does not compromise its efficacy in stable responders with psoriasis and psoriatic arthritis, the specific effects of reduced Cosentyx dosage on remission maintenance are not well-studied and documented. It is important for healthcare providers to consider the individual patient's needs and response to treatment when making decisions about dosage adjustments.

Sources:

1. Cosentyx (secukinumab) [Prescribing Information]. Novartis Pharmaceuticals Corporation; 2021. <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>.
2. Blauvelt A, de Wit P, Paul C, et al. Secukinumab maintenance dosing intervals and clinical outcomes: Results from a randomized, double-blind, placebo-controlled study in patients with moderate-to-severe plaque psoriasis. Journal of the American Academy of Dermatology. 2017;76(3):422-430.e3. <https://doi.org/10.1016/j.jaad.2016.11.013>.
3. Mease PJ, Kivitz A, Bukowski B, et al. Secukinumab dose reduction in patients with psoriatic arthritis: Results from a randomized, double-blind, placebo-controlled study. Annals of the Rheumatic Diseases. 2018;77(5):771-778. <https://doi.org/10.1136/annrheumdis-2017-211535>.
4. DrugPatentWatch. Cosentyx (secukinumab) Drug Profile. <https://www.drugpatentwatch.com/drugs/cosentyx>.